Press Releases

Date Title and Summary View
Toggle Summary Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
NEWARK, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013. Recent Accomplishments and Progress Toward Milestones Closing of the Company's initial public offering (IPO) in
View HTML
Toggle Summary Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014
NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter and full year
View HTML
Toggle Summary Revance to Add Angus C. Russell as Chairman to Its Board of Directors
NEWARK, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Angus C. Russell has been appointed as Chairman to its
View HTML
Toggle Summary Revance Therapeutics, Inc. Announces Participation in Cowen 34th Annual Health Care Conference
NEWARK, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen 34th Annual Health Care Conference in Boston. Revance management is scheduled to present on Wednesday, March 5, 2014 at 9:20 am
View HTML
Toggle Summary Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
Gross Proceeds of Offering Total $110 Million
View HTML
Toggle Summary Revance Therapeutics Announces Pricing of Initial Public Offering
NEWARK, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Revance), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the pricing of its initial public offering of 6,000,000 shares of its
View HTML
Toggle Summary Revance Therapeutics Announces $33 Million Series E Financing
CONTACT: Lauren Silvernail Chief Financial Officer and EVP Corporate Development 510-742-3415 lsilvernail@revance.com NEWARK, California — April 2, 2013 — Revance Therapeutics, Inc. (Revance), a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in
View HTML
Toggle Summary Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer
CONTACT: Revance Therapeutics, Inc. Niquette L. Hunt Senior Vice President, Commercial Development NEWARK, California—March 25, 2013 — Revance Therapeutics, Inc. (Revance) today announced the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President of Corporate
View HTML
Toggle Summary Revance Therapeutics Regains All Worldwide Rights To Its Botulinum Toxin Products
Revance Therapeutics Regains All Worldwide Rights To Its Botulinum Toxin Products CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif.—October 8, 2012 — Revance Therapeutics, Inc. (Revance) today announced a settlement and termination
View HTML
Toggle Summary Revance Announces $45 Million Financing
Revance Announces $45 Million Financing CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – June 10, 2011 – Revance Therapeutics, Inc. (“Revance”) today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools